IMVT
Immunovant, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 92 | +8 | 58.13M | $2.24B | +14 | −5 |
| Q1 2026 | 86 | +8 | 53.00M | $1.32B | +12 | −4 |
| Q4 2025 | 78 | -2 | 55.44M | $1.41B | — | −2 |
| Q3 2025 | 16 | 0 | 40.91M | $659.48M | +1 | −2 |
| Q2 2025 | 14 | -2 | 41.55M | $664.87M | — | −2 |
| Q1 2025 | 13 | +2 | 9.17M | $156.74M | +2 | — |
| Q4 2024 | 11 | -2 | 8.24M | $204.11M | — | −2 |
| Q3 2024 | 12 | +1 | 7.03M | $200.30M | +1 | — |
| Q2 2024 | 11 | — | 7.29M | $192.47M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 2.32M | — | $61.27M | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.41M | — | $37.34M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.41M | — | $37.34M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.36M | — | $35.95M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.36M | — | $35.95M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 601.86K | — | $15.89M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 420.00K | — | $11.09M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 388.10K | — | $10.25M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 343.51K | — | $9.07M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 343.51K | — | $9.07M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Millennium Management ✦ | 275.35K | — | $7.27M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 86.28K | — | $2.28M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 86.28K | — | $2.28M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 86.28K | — | $2.28M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 41.48K | — | $1.10M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 41.48K | — | $1.10M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Wellington Management ✦ | 36.93K | — | $974,925 | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Wellington Management ✦ | 36.93K | — | $974,925 | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Wellington Management ✦ | 36.93K | — | $974,925 | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Wellington Management ✦ | 36.93K | — | $974,925 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 215 holders, 110.50M shares, $2.64B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.06K sh · $134,953
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology